Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
doi: 10.3389/fendo.2025.1650729 Received 20 June 2025 Accepted 18 September 2025 Published 01 October 2025 Volume 16 - 2025 Edited by Maria Gazouli, National and Kapodistrian University of Athens, Greece Reviewed by Xiaohang Wang, Affiliated Hospital of Yangzhou University, China Junqing Lin, Shanghai Jiao Tong University, China Guangda He, Chinese Academy of Medical Sciences and Peking Union Medical College, China Updates Copyright 2025 Niu, Chen, Wu, Wang, Xu, Yin and Zhao
Melanotan II imitates your bodys natural melanocyte-stimulating hormone, which is responsible for pigmenting your skin
Psoriatic arthritis: the influence of co-morbidities on drug choice
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
US$ 20.17
US$ 25.39
US$ 26.94
US$ 20.61
US$ 29.53
US$ 22.07
US$ 21.02
US$ 26.63
US$ 29.69
US$ 22.73
